Human cancer growth and therapy in immunodeficient mouse models

Cold Spring Harbor Protocols

Volumn 2014, Issue 7, 2014, Pages 694-708

  Shultz, Leonard D ^a   Goodwin, Neal ^a   Ishikawa, Fumihiko ^b   Hosur, Vishnu ^a   Lyons, Bonnie L ^a   Greiner, Dale L ^c  

^a JACKSON LABORATORY   (United States)

^b RIKEN Center for Integrative Medical Sciences   (Japan)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; RAG1 PROTEIN; RAG2 PROTEIN;

ANIMAL MODEL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; DRUG EFFICACY; GENE EXPRESSION; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOTHERAPY; INNATE IMMUNITY; MOUSE; NATURAL KILLER CELL; NOD SCID GAMMA MOUSE; NOD SCID MOUSE; NONHUMAN; NUDE MOUSE; SCID MOUSE; SOLID TUMOR; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; DISEASE MODEL; IMMUNE SYSTEM; IMMUNOLOGY; NEOPLASMS; PATHOLOGY; RESEARCH; TRENDS; XENOGRAFT;

MURINAE; MUS;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE SYSTEM; MICE; MICE, SCID; NEOPLASMS; RESEARCH; TRANSPLANTATION, HETEROLOGOUS;

EID: 84923825376     PISSN: 19403402     EISSN: 15596095     Source Type: Journal    
DOI: 10.1101/pdb.top073585     Document Type: Article

References (144)

1. Agliano A, Martin-Padura I, Mancuso P, Marighetti P, Rabascio C, Pruneri G, Shultz LD, Bertolini F. 2008. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rγ null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer 123: 2222–2227.
2. Agliano A, Martin-Padura I, Marighetti P, Gregato G, Calleri A, Prior C, Redrado M, Calvo A, Bertolini F. 2011. Therapeutic effect of lenalidomide in a novel xenograft mouse model of human blastic NK cell lymphoma/blastic plasmacytoid dendritic cell neoplasm. Clinical Cancer Res 17: 6163–6173.
3. Ahmed F, Steele JC, Herbert JM, Steven NM, Bicknell R. 2008. Tumor stroma as a target in cancer. Curr Cancer Drug Targets 8: 447–453.
4. Ailles LE, Gerhard B, Kawagoe H, Hogge DE. 1999. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood 94: 1761–1772.
5. Akunuru S, Palumbo J, Zhai QJ, Zheng Y. 2011. Rac1 targeting suppresses human non–small cell lung adenocarcinoma cancer stem cell activity. PLoS ONE 6: e16951.
6. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. 2003. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci 100: 3983–3988.
7. Appelbaum FR, Rowe JM, Radich J, Dick JE. 2001. Acute myeloid leukemia. Hematol Am Soc Hematol Educ Program 2001: 62–86.
8. Baersch G, Mollers T, Hotte A, Dockhorn-Dworniczak B, Rube C, Ritter J, Jurgens H, Vormoor J. 1997. Good engraftment of B-cell precursor ALL in NOD-SCID mice. Clin Padiatr 209: 178–185.
9. Bagnara D, Kaufman MS, Calissano C, Marsilio S, Patten PE, Simone R, Chum P, Yan XJ, Allen SL, Kolitz JE, et al. 2011. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood 117: 5463–5472.
10. Bankert RB, Balu-Iyer SV, Odunsi K, Shultz LD, Kelleher RJ Jr, Barnas JL, Simpson-Abelson M, Parsons R, Yokota SJ. 2011. Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis. PLoS ONE 6: e24420.
11. Blunt T, Gell D, Fox M, Taccioli GE, Lehmann AR, Jackson SP, Jeggo PA. 1996. Identification of a nonsense mutation in the carboxyl-terminal region of DNA-dependent protein kinase catalytic subunit in the scid mouse. Proc Natl Acad Sci 93: 10285–10290.
12. Bonapace L, Bornhauser BC, Schmitz M, Cario G, Ziegler U, Niggli FK, Schafer BW, Schrappe M, Stanulla M, Bourquin JP. 2010. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest 120: 1310–1323.
13. Bonnet D, Dick JE. 1997. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730–737.
14. Boonyaratanakornkit JB, Yue L, Strachan LR, Scalapino KJ, LeBoit PE, Lu Y, Leong SP, Smith JE, Ghadially R. 2010. Selection of tumorigenic melanoma cells using ALDH. J Invest Dermatol 130: 2799–2808.
15. Bosma GC, Custer RP, Bosma MJ. 1983. A severe combined immunodeficiency mutation in the mouse. Nature 301: 527–530.
16. Brown CE, Starr R, Aguilar B, Shami AF, Martinez C, D’Apuzzo M, Barish ME, Forman SJ, Jensen MC. 2012. Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-ζkine-redirected T cells. Clin Cancer Res 18: 2199–2209.
17. Cao X, Shores EW, Hu-Li J, Anver MR, Kelsall BL, Russell SM, Drago J, Noguchi M, Grinberg A, Bloom ET, et al. 1995. Defective lymphoid development in mice lacking expression of the common cytokine receptor γ chain. Immunity 2: 223–238.
18. Castro Alves C, Terziyska N, Grunert M, Gundisch S, Graubner U, Quintanilla-Martinez L, Jeremias I. 2012. Leukemia-initiating cells of patientderived acute lymphoblastic leukemia xenografts are sensitive toward TRAIL. Blood 119: 4224–4227.
19. Cesano A, Hoxie JA, Lange B, Nowell PC, Bishop J, Santoli D. 1992. The severe combined immunodeficient (SCID) mouse as a model for human myeloid leukemias. Oncogene 7: 827–836.
20. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, et al. 2010. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142: 699–713.
21. Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL, Majeti R. 2011a. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 71: 1374–1384.
22. Chao MP, Tang C, Pachynski RK, Chin R, Majeti R, Weissman IL. 2011b. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood 118: 4890–4901.
23. Charley MR, Tharp M, Locker J, Deng JS, Goslen JB, Mauro T, McCoy P, Abell E, Jegasothy B. 1990. Establishment of a human cutaneous T-cell lymphoma in C.B-17 SCID mice. J Invest Dermatol 94: 381–384.
24. Chen K, Ahmed S, Adeyi O, Dick JE, Ghanekar A. 2012. Human solid tumor xenografts in immunodeficient mice are vulnerable to lymphomagenesis associated with Epstein–Barr virus. PloS ONE 7: e39294.
25. Chiu PP, Jiang H, Dick JE. 2010. Leukemia-initiating cells in human Tlymphoblastic leukemia exhibit glucocorticoid resistance. Blood 116: 5268–5279.
26. Clappier E, Gerby B, Sigaux F, Delord M, Touzri F, Hernandez L, Ballerini P, Baruchel A, Pflumio F, Soulier J. 2011. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med 208: 653–661.
27. Colombo F, Baldan F, Mazzucchelli S, Martin-Padura I, Marighetti P, Cattaneo A, Foglieni B, Spreafico M, Guerneri S, Baccarin M, et al. 2011. Evidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinoma. PLoS ONE 6: e21369.
28. Cournoyer S, Nyalendo C, Addioui A, Belounis A, Beaunoyer M, Aumont A, Teira P, Duval M, Fernandes K, Fetni R, et al. 2012. Genotype analysis of tumor-initiating cells expressing CD133 in neuroblastoma. Genes Chromosomes Cancer 51: 792–804.
29. Dick JE. 2008. Stem cell concepts renew cancer research. Blood 112: 4793-4807.
30. Dieter SM, Ball CR, Hoffmann CM, Nowrouzi A, Herbst F, Zavidij O, Abel U, Arens A, Weichert W, Brand K, et al. 2011. Distinct types of tumorinitiating cells form human colon cancer tumors and metastases. Cell Stem Cell 9: 357–365.
31. DiSanto JP, Muller W, Guy-Grand D, Fischer A, Rajewsky K. 1995. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor γ chain. Proc Natl Acad Sci 92: 377–381.
32. Distler E, Wolfel C, Kohler S, Nonn M, Kaus N, Schnurer E, Meyer RG, Wehler TC, Huber C, Wolfel T, et al. 2008. Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8+ CD62L(high)+ T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rγnull mice. Exp Hematol 36: 451–463.
33. Edris B, Espinosa I, Muhlenberg T, Mikels A, Lee CH, Steigen SE, Zhu S, Montgomery KD, Lazar AJ, Lev D, et al. 2012a. ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. J Pathol 227: 223–233.
34. Edris B, Weiskopf K, Volkmer AK, Volkmer JP, Willingham SB, Contreras-Trujillo H, Liu J, Majeti R, West RB, Fletcher JA, et al. 2012b. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci 109: 6656–6661.
35. Eisterer W, Jiang X, Christ O, Glimm H, Lee KH, Pang E, Lambie K, Shaw G, Holyoake TL, Petzer AL, et al. 2005. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia 19: 435–441.
36. Engels B, Rowley DA, Schreiber H. 2012. Targeting stroma to treat cancers. Semin Cancer Biol 22: 41–49.
37. Flavell DJ. 1996. Modelling human leukemia and lymphoma in severe combined immunodeficient (SCID) mice: Practical applications. Hematol Oncol 14: 67–82.
38. Fogh J, Fogh JM, Orfeo T. 1977. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 59: 221–226.
39. Frost P, Moatamed F, Hoang B, Shi Y, Gera J, Yan H, Gibbons J, Lichtenstein A. 2004. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 104: 4181–4187.
40. Fusetti L, Pruneri G, Gobbi A, Rabascio C, Carboni N, Peccatori F, Martinelli G, Bertolini F. 2000. Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: Frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production. Cancer Res 60: 2527–2534.
41. Gandara DR, Li T, Lara PN Jr, Mack PC, Kelly K, Miyamoto S, Goodwin N, Beckett L, Redman MW. 2012. Algorithm for codevelopment of new drug-predictive biomarker combinations: Accounting for inter-and intrapatient tumor heterogeneity. Clin Lung Cancer 13: 321–325.
42. Gerber JM, Smith BD, Ngwang B, Zhang H, Vala MS, Morsberger L, Galkin S, Collector MI, Perkins B, Levis MJ, et al. 2012. A clinically relevant population of leukemic CD34+CD38− cells in acute myeloid leukemia. Blood 119: 3571–3577.
43. Giovanella BC, Fogh J. 1985. The nude mouse in cancer research. Adv Cancer Res 44: 69–120.
44. Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, Soneji S, Woll P, Mead A, Alford KA, Rout R, et al. 2011. Coexistence of LMPP-like and GMPlike leukemia stem cells in acute myeloid leukemia. Cancer Cell 19: 138-152.
45. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. 2010. Identification of a cell of origin for human prostate cancer. Science 329: 568–571.
46. Greiner DL, Hesselton RA, Shultz LD. 1998. SCID mouse models of human stem cell engraftment. Stem Cells 16: 166–177.
47. Hesselton RM, Greiner DL, Mordes JP, Rajan TV, Sullivan JL, Shultz LD. 1995. High levels of human peripheral blood mononuclear cell engraftment and enhanced susceptibility to human immunodeficiency virus type 1 infection in NOD/LtSz-scid/scid mice. J Infect Dis 172: 974–982.
48. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick MJ, Martell J, Sidransky D. 2011. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 10: 1311–1316.
49. Huang SY, Tien HF, Su FH, Hsu SM. 2004. Nonirradiated NOD/SCIDhuman chimeric animal model for primary human multiple myeloma: A potential in vivo culture system. Am J Pathol 164: 747–756.
50. Hudson WA, Li Q, Le C, Kersey JH. 1998. Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple immunologic defects. Leukemia 12: 2029–2033.
51. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, Nakamura R, Tanaka T, Tomiyama H, Saito N, et al. 2007. Chemotherapy-resistant human AML stem cells home to and engraft within the bonemarrow endosteal region. Nat Biotechnol 25: 1315–1321.
52. Ishikawa F, Saito Y, Shultz LD. 2008. Modeling human leukemia using immune-compromised mice. In Mouse models of human blood cancers: Basic research and clinical applications (ed. Li S), pp. 121–132. Springer, New York.
53. Ishizawa K, Rasheed ZA, Karisch R, Wang Q, Kowalski J, Susky E, Pereira K, Karamboulas C, Moghal N, Rajeshkumar NV, et al. 2010. Tumorinitiating cells are rare in many human tumors. Cell Stem Cell 7: 279-282.
54. Itoh T, Shiota M, Takanashi M, Hojo I, Satoh H, Matsuzawa A, Moriyama T, Watanabe T, Hirai K, Mori S. 1993. Engraftment of human non-Hodgkin lymphomas in mice with severe combined immunodeficiency. Cancer 72: 2686–2694.
55. Jiang X, Saw KM, Eaves A, Eaves C. 2007. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 99: 680–693.
56. Kamel-Reid S, Letarte M, Sirard C, Doedens M, Grunberger T, Fulop G, Freedman MH, Phillips RA, Dick JE. 1989. A model of human acute lymphoblastic leukemia in immune-deficient SCID mice. Science 246: 1597–1600.
57. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. 2007. Tumor growth need not be driven by rare cancer stem cells. Science 317: 337.
58. Khabele D, Fadare O, Liu AY, Wilson AJ, Wass E, Osteen K, Crispens MA. 2012. An orthotopic model of platinum-sensitive high grade serous fallopian tube carcinoma. Int J Clin Exp Pathol 5: 37–45.
59. Kikushige Y, Ishikawa F, Miyamoto T, Shima T, Urata S, Yoshimoto G, Mori Y, Iino T, Yamauchi T, Eto T, et al. 2011. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 20: 246–259.
60. Kim D, Park CY, Medeiros BC, Weissman IL. 2012a. CD19−CD45low/− CD38high/CD138+ plasma cells enrich for human tumorigenic myeloma cells. Leukemia 26, 2530–2537.
61. Kim J, Villadsen R, Sorlie T, Fogh L, Gronlund SZ, Fridriksdottir AJ, Kuhn I, Rank F, Wielenga VT, Solvang H, et al. 2012b. Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity. Proc Natl Acad Sci 109: 6124–6129.
62. Kim RS, Avivar-Valderas A, Estrada Y, Bragado P, Sosa MS, Aguirre-Ghiso JA, Segall JE. 2012c. Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer. PloS ONE 7: e35569.
63. Kong Y, Yoshida S, Saito Y, Doi T, Nagatoshi Y, Fukata M, Saito N, Yang SM, Iwamoto C, Okamura J, et al. 2008. CD34+CD38+CD19+ as well as CD34+CD38−CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia 22: 1207-1213.
64. Krumbach R, Schuler J, Hofmann M, Giesemann T, Fiebig HH, Beckers T. 2011. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance. Eur J Cancer 47: 1231–1243.
65. Kupas V, Weishaupt C, Siepmann D, Kaserer ML, Eickelmann M, Metze D, Luger TA, Beissert S, Loser K. 2011. RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells. J Invest Dermatol 131: 944–955.
66. le Viseur C, Hotfilder M, Bomken S, Wilson K, Rottgers S, Schrauder A, Rosemann A, Irving J, Stam RW, Shultz LD, et al. 2008. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell 14: 47–58.
67. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. 2007. Identification of pancreatic cancer stem cells. Cancer Res 67: 1030–1037.
68. Lin T-Y, Li Y-P, Zhang H, Luo J, Goodwin N, Gao T, White R, Lam KS, Pan C-X. 2013. Tumor-targeting multifunctional micelles for imaging and chemotherapy of advanced bladder cancer. Nanomedicine (Lond) 8: 1239–1251.
69. Liu D, Song L, Wei J, Courtney AN, Gao X, Marinova E, Guo L, Heczey A, Asgharzadeh S, Kim E, et al. 2012. IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J Clin Invest 122: 2221–2233.
70. Ma J, Lin JY, Alloo A, Wilson BJ, Schatton T, Zhan Q, Murphy GF, Waaga-Gasser AM, Gasser M, Stephen Hodi F, et al. 2010. Isolation of tumorigenic circulating melanoma cells. Biochem Biophys Res Commun 402: 711–717.
71. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, van Rooijen N, Weissman IL. 2009. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138: 286–299.
72. Martin-Padura I, Marighetti P, Agliano A, Colombo F, Larzabal L, Redrado M, Bleau AM, Prior C, Bertolini F, Calvo A. 2012. Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. Lab Invest 92: 952–966.
73. Mazza JJ. 2010. Infectious disease and cancer. WMJ 109: 66–69.
74. Medyouf H, Gao X, Armstrong F, Gusscott S, Liu Q, Gedman AL, Matherly LH, Schultz KR, Pflumio F, You MJ, et al. 2010. Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. Blood 115: 1175–1184.
75. Mirandola L, Yu Y, Jenkins MR, Chiaramonte R, Cobos E, John CM, Chiriva-Internati M. 2011. Tracking human multiple myeloma xenografts in NOD-Rag-1/IL-2 receptor γ chain-null mice with the novel biomarker AKAP-4. BMC Cancer 11: 394.
76. Monsma DJ, Monks NR, Cherba DM, Dylewski D, Eugster E, Jahn H, Srikanth S, Scott SB, Richardson PJ, Everts RE, et al. 2012. Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue. J Transl Med 10: 125.
77. Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, Powell DJ Jr, Riley JL, June CH, Albelda SM. 2011. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res 17: 4719–4730.
78. Morisot S, Wayne AS, Bohana-Kashtan O, Kaplan IM, Gocke CD, Hildreth R, Stetler-Stevenson M, Walker RL, Davis S, Meltzer PS, et al. 2010. High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias. Leukemia 24: 1859–1866.
79. Mueller BM, Reisfeld RA. 1991. Potential of the scid mouse as a host for human tumors. Cancer Metastasis Rev 10: 193–200.
80. Nakamura M, Suemizu H. 2008. Novel metastasis models of human cancer in NOG mice. Curr Top Microbiol Immunol 324: 167–177.
81. O’Brien CA, Pollett A, Gallinger S, Dick JE. 2007. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106–110.
82. O’Reilly MS, Holmgren L, Chen C, Folkman J. 1996. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2: 689–692.
83. Ohbo K, Suda T, Hashiyama M, Mantani A, Ikebe M, Miyakawa K, Moriyama M, Nakamura M, Katsuki M, Takahashi K, et al. 1996. Modulation of hematopoiesis in mice with a truncated mutant of the interleukin-2 receptor γ chain. Blood 87: 956–967.
84. Ono M, Qiang W, Serna VA, Yin P, Coon JS 5th, Navarro A, Monsivais D, Kakinuma T, Dyson M, Druschitz S, et al. 2012. Role of stem cells in human uterine leiomyoma growth. PloS ONE 7: e36935.
85. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, et al. 2006. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25: 1696-1708.
86. Pearce DJ, Taussig D, Zibara K, Smith LL, Ridler CM, Preudhomme C, Young BD, Rohatiner AZ, Lister TA, Bonnet D. 2006. AML engraftment in the NOD/SCID assay reflects the outcome of AML: Implications for our understanding of the heterogeneity of AML. Blood 107: 1166–1173.
87. Peters M, Jacobs S, Ehlers M, Vollmer P, Mullberg J, Wolf E, Brem G, Meyer zum Buschenfelde KH, Rose-John S. 1996. The function of the soluble interleukin 6 (IL-6) receptor in vivo: Sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med 183: 1399–1406.
88. Phillips RA, Jewett MA, Gallie BL. 1989. Growth of human tumors in immune-deficient scid mice and nude mice. Curr Top Microbiol Immunol 152: 259–263.
89. Pilarski LM, Belch AR. 2002. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34+ hematopoietic progenitors. Clin Cancer Res 8: 3198–3204.
90. Pilarski LM, Hipperson G, Seeberger K, Pruski E, Coupland RW, Belch AR. 2000. Myeloma progenitors in the blood of patients with aggressive or minimal disease: Engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 95: 1056-1065.
91. Price JE, Zhang RD. 1990. Studies of human breast cancer metastasis using nude mice. Cancer Metastasis Rev 8: 285–297.
92. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE. 2007. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci 104: 973–978.
93. Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, Reik A, Chu V, Paschon DE, Zhang L, Kuball J, et al. 2012. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med 18: 807–815.
94. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. 2008. Efficient tumour formation by single human melanoma cells. Nature 456: 593–598.
95. Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM, Morrison SJ. 2010. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18: 510–523.
96. Quintana E, Piskounova E, Shackleton M, Weinberg D, Eskiocak U, Fullen DR, Johnson TM, Morrison SJ. 2012. Human melanoma metastasis in NSG mice correlates with clinical outcome in patients. Science Transl Med 4: 159ra149.
97. Reddy S, Piccione D, Takita H, Bankert RB. 1987. Human lung tumor growth established in the lung and subcutaneous tissue of mice with severe combined immunodeficiency. Cancer Res 47: 2456–2460.
98. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. 2007. Identification and expansion of human colon-cancerinitiating cells. Nature 445: 111–115.
99. Rongvaux A, Takizawa H, Strowig T, Willinger T, Eynon EE, Flavell RA, Manz MG. 2013. Human hemato-lymphoid system mice: Current use and future potential for medicine. Annu Rev Immunol 31: 635–674.
100. Saito Y, Kitamura H, Hijikata A, Tomizawa-Murasawa M, Tanaka S, Takagi S, Uchida N, Suzuki N, Sone A, Najima Y, et al. 2010a. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med 2: 17ra19.
101. Saito Y, Uchida N, Tanaka S, Suzuki N, Tomizawa-Murasawa M, Sone A, Najima Y, Takagi S, Aoki Y, Wake A, et al. 2010b. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol 28: 275–280.
102. Sakakibara T, Xu Y, Bumpers HL, Chen FA, Bankert RB, Arredondo MA, Edge SB, Repasky EA. 1996. Growth and metastasis of surgical specimens of human breast carcinomas in SCID mice. Cancer J Sci Am 2: 291–300.
103. Sanchez PV, Perry RL, Sarry JE, Perl AE, Murphy K, Swider CR, Bagg A, Choi JK, Biegel JA, Danet-Desnoyers G, et al. 2009. A robust xenotransplantation model for acute myeloid leukemia. Leukemia 23: 2109–2117.
104. Sarry JE, Murphy K, Perry R, Sanchez PV, Secreto A, Keefer C, Swider CR, Strzelecki AC, Cavelier C, Recher C, et al. 2011. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J Clin Invest 121: 384–395.
105. Sebens S, Schafer H. 2012. The tumor stroma as mediator of drug resistance —A potential target to improve cancer therapy? Curr Pharm Biotechnol 13: 2259–2272.
106. Seitz G, Pfeiffer M, Fuchs J, Warmann SW, Leuschner I, Vokuhl C, Lang P, Handgretinger R, Armeanu-Ebinger S. 2010. Establishment of a rhabdomyosarcoma xenograft model in human-adapted mice. Oncol Rep 24: 1067–1072.
107. Sharkey FE, Fogh J. 1984. Considerations in the use of nude mice for cancer research. Cancer Metastasis Rev 3: 341–360.
108. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, et al. 2008. CD133 expression is not restricted to stem cells, and both CD133+ and CD133− metastatic colon cancer cells initiate tumors. J Clin Invest 118: 2111–2120.
109. Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, McKenna S, Mobraaten L, Rajan TV, Greiner DL, et al. 1995. Multiple defects in innate and adaptive immunologic function in NOD/ LtSz-scid mice. J Immunol 154: 180–191.
110. Shultz LD, Ishikawa F, Greiner DL. 2007. Humanized mice in translational biomedical research. Nat Rev Immunol 7: 118–130.
111. Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner D. 2012. Humanized mice for immune system investigation: Progress, promise and challenges. Nat Rev Immunol 12: 786–798.
112. Shultz LD, Goodwin N, Ishikawa F, Hosur V, Lyons BL, Greiner DL. 2014. Subcapsular transplantation of tissue in the kidney. Cold Spring Harb Protoc doi: 10.1101/pdb.prot078089.
113. Silvestre DC, Pineda JR, Hoffschir F, Studler JM, Mouthon MA, Pflumio F, Junier MP, Chneiweiss H, Boussin FD. 2011. Alternative lengthening of telomeres in human glioma stem cells. Stem Cells 29: 440–451.
114. Simpson-Abelson MR, Sonnenberg GF, Takita H, Yokota SJ, Conway TF Jr, Kelleher RJ Jr, Shultz LD, Barcos M, Bankert RB. 2008. Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rγnull mice. J Immunol 180: 7009–7018.
115. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. 2003. Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821–5828.
116. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. 2004. Identification of human brain tumour initiating cells. Nature 432: 396–401.
117. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. 2006. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24: 74–85.
118. Stewart JM, Shaw PA, Gedye C, Bernardini MQ, Neel BG, Ailles LE. 2011. Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci 108: 6468–6473.
119. Subramanian S, Parthasarathy R, Sen S, Boder ET, Discher DE. 2006. Species-and cell type-specific interactions between CD47 and human SIRPα. Blood 107: 2548–2556.
120. Takenaka K, Prasolava TK, Wang JC, Mortin-Toth SM, Khalouei S, Gan OI, Dick JE, Danska JS. 2007. Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat Immunol 8: 1313–1323.
121. Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, Ridler C, Lillington D, Oakervee H, Cavenagh J, Agrawal SG, et al. 2008. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 112: 568–575.
122. Taussig DC, Vargaftig J, Miraki-Moud F, Griessinger E, Sharrock K, Luke T, Lillington D, Oakervee H, Cavenagh J, Agrawal SG, et al. 2010. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34− fraction. Blood 115: 1976-1984.
123. Taylor CW, Grogan TM, Lopez MH, Leong SP, Odeleye A, Feo-Zuppardi FJ, Hersh EM. 1992. Growth and dissemination of human malignant melanoma cells in mice with severe combined immune deficiency. Lab Invest 67: 130–137.
124. Tian X, Woll PS, Morris JK, Linehan JL, Kaufman DS. 2006. Hematopoietic engraftment of human embryonic stem cell–derived cells is regulated by recipient innate immunity. Stem Cells 24: 1370–1380.
125. Uckun FM. 1996. Severe combined immunodeficient mouse models of human leukemia. Blood 88: 1135–1146.
126. Urbanska K, Lanitis E, Poussin M, Lynn RC, Gavin BP, Kelderman S, Yu J, Scholler N, Powell DJ Jr. 2012. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res 72: 1844–1852.
127. Utama FE, LeBaron MJ, Neilson LM, Sultan AS, Parlow AF, Wagner KU, Rui H. 2006. Human prolactin receptors are insensitive to mouse prolactin: Implications for xenotransplant modeling of human breast cancer in mice. J Endocrinol 188: 589–601.
128. Valdez KE, Fan F, Smith W, Allred DC, Medina D, Behbod F. 2011. Human primary ductal carcinoma in situ (DCIS) subtype-specific pathology is preserved in a mouse intraductal (MIND) xenograft model. J Pathol 225: 565–573.
129. Vargaftig J, Taussig DC, Griessinger E, Anjos-Afonso F, Lister TA, Cavenagh J, Oakervee H, Gribben J, Bonnet D. 2012. Frequency of leukemic initiating cells does not depend on the xenotransplantation model used. Leukemia 26: 858–860.
130. Vatakis DN, Koya RC, Nixon CC, Wei L, Kim SG, Avancena P, Bristol G, Baltimore D, Kohn DB, Ribas A, et al. 2011. Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc Natl Acad Sci 108: E1408-1416.
131. Visonneau S, Cesano A, Torosian MH, Miller EJ, Santoli D. 1998. Growth characteristics and metastatic properties of human breast cancer xenografts in immunodeficient mice. Am J Pathol 152: 1299–1311.
132. Visvader JE. 2011. Cells of origin in cancer. Nature 469: 314–322.
133. Wang JC, Lapidot T, Cashman JD, Doedens M, Addy L, Sutherland DR, Nayar R, Laraya P, Minden M, Keating A, et al. 1998. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood 91: 2406–2414.
134. Wege AK, Ernst W, Eckl J, Frankenberger B, Vollmann-Zwerenz A, Mannel DN, Ortmann O, Kroemer A, Brockhoff G. 2011. Humanized tumor mice—A new model to study and manipulate the immune response in advanced cancer therapy. Int J Cancer 129: 2194–2206.
135. Williams SS, Alosco TR, Croy BA, Bankert RB. 1993. The study of human neoplastic disease in severe combined immunodeficient mice. Lab Anim Sci 43: 139–146.
136. Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, et al. 2012. The CD47-signal regulatory protein α (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci 109: 6662-6667.
137. Wong K, Brenneman F, Chesney A, Spaner DE, Gorczynski RM. 2012. Soluble CD200 is critical to engraft chronic lymphocytic leukemia cells in immunocompromised mice. Cancer Res 72: 4931–4943.
138. Wunderlich M, Chou FS, Link KA, Mizukawa B, Perry RL, Carroll M, Mulloy JC. 2010. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GMCSF and IL-3. Leukemia 24: 1785–1788.
139. Xue SA, Gao L, Hart D, Gillmore R, Qasim W, Thrasher A, Apperley J, Engels B, Uckert W, Morris E, et al. 2005. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene–transduced human T cells. Blood 106: 3062–3067.
140. Zhang B, Strauss AC, Chu S, Li M, Ho Y, Shiang KD, Snyder DS, Huettner CS, Shultz L, Holyoake T, et al. 2010. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 17: 427–442.
141. Zhang WC, Shyh-Chang N, Yang H, Rai A, Umashankar S, Ma S, Soh BS, Sun LL, Tai BC, Nga ME, et al. 2012a. Glycine decarboxylase activity drives non–small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 148: 259–272.
142. Zhang X, Cruz FD, Terry M, Remotti F, Matushansky I. 2012b. Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming. Oncogene 32: 2249–2260.
143. Zhang B, Min L, McDonald T, Holyoake T, Moon RT, Campana D, Shultz L, Bhatia R. 2013. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling. Blood 121: 1824–1838.
144. Zorzoli A, Di Carlo E, Cocco C, Ognio E, Ribatti D, Ferretti E, Dufour C, Locatelli F, Montagna D, Airoldi I. 2012. Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg−/− mice. Clin Cancer Res 18: 1630–1640.